Dylan Shindler's questions to Xenon Pharmaceuticals Inc (XENE) leadership • Q1 2025
Question
Dylan Shindler, on for Laura Chico, asked about the expected enrollment timeline for the X-TOLE3 study relative to X-TOLE2 to better understand the separation between the two data readouts.
Answer
President and CEO Ian Mortimer explained that X-TOLE2 was prioritized and initiated first, meaning X-TOLE3 is on a later timeline. While not providing specific guidance for X-TOLE3's completion, he confirmed its readout will be later than X-TOLE2's and that more detailed guidance would be provided later in the year.